Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adimab, Celgene, Innovent Biologics deal

Adimab announced two separate discovery deals for its yeast-based antibody discovery technology in the week ending Aug. 23. Adimab will use the technology to identify human antibodies against an

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE